Sunday, July 31, 2016

2H16 Trading Thesis


We are encouraged by the recent market rally and believe we could rally further as additional bullish sentiment creeps into the financial picture. A strong dose of FOMO (fear of missing out) could be the catalyst to drive the market higher. That said our radar is on high alert for a pullback in the market in the coming weeks and months. We are laying out our strategy on how we expect to position ourselves through the remainder of the year.

Near-term Technicals Warrant Caution

The daily S&P 500 shows a decent consolidation trend after digesting the gains over the past few weeks but is definitely overbought. We believe a pullback to its previous high of 2130 (green line) isn’t the end of the rally and could prove a healthy pullback. Other levels we’ll be watching are 2120 (blue line) which was the old resistance and 2100 which is the 50-day moving average (red moving average). We expect a move back to these levels over the next several weeks, viewing how these levels hold and monitoring volume activity.

We also note that the daily MACD is very close to a bearish cross and that loss of momentum could be a sign of coming weakness. The percent of companies above their 50 and 200-day moving averages have peaked and the percent of companies in bullish P&F formations are also at extended levels. This does not guarantee a coming correction. This could just be a period of cooling until the next leg up occurs.


The SPX weekly chart looks good. We can see the breakout from its trading channel, RSI (14) is above 50, although the faster moving oscillators are overbought currently but again, that doesn’t predict a coming correction. The bullish MACD cross that occurred earlier this year still holds and the recent rally has been broad-based by equal weight as seen in the chart below (RSP:$SPX). We can see our levels on this chart. A break back to 2000 would be very discouraging but a significant breach of that level could spell loads of trouble and may have us thinking shorting the market again.  



On the daily Nasdaq chart, we are approaching key levels after the breakout that occurred this month. Tech and Biotech enjoyed a nice rally recently. We are hitting some overhead resistance and overbought conditions that could prove challenging but a tepid pullback over the next few weeks could be exactly what we need to keep this advance going. We like the fact that volume has been increasing as the Nasdaq went higher last month. The MACD bullish cross remains intact but is waning somewhat but much less than the S&P 500.


The weekly Nasdaq chart shows the breakout from its trading channel along with the overhead resistance on the horizon. The MACD bullish cross remains intact and the oscillators are overbought but healthy. A pullback and support to the top of the trading channel near 4900 wouldn’t jeopardize the current rally in our view.


Reading Lance Roberts from Real Investment Advice sheds additional light on the near-term market prospects. He writes, “The consolidation over the past week DID pull the deviation back from 3-standard deviations above the 50-dma to just 2-standard deviations. This didn’t solve much of the problem as of yet.

Importantly, there are TWO ways to solve an overbought and overextended market advance. The first is for the market to continue this very tight trading range long enough for the moving average to catch up with the price.

The second is a corrective pullback, which is notated in the chart above. However, not all pullbacks are created equal.

1. A pullback to 2135, the previous all-time high, that holds that level will allow for an increase in equity allocations to the new targets.

2. A pullback that breaks 2135 will keep equity allocation increases on “HOLD” until support has been tested.

3. A pullback that breaks 2080 will trigger “stop losses” in portfolios and confirm the recent breakout was a short-term “head fake.””


He goes on to state, “The next chart shows the 9.3% advance from the “Brexit” low. The momentum “buy” signal was triggered fairly early in the advance along with an upturn in volume. However, both of those indicators are now beginning to turn lower which would also suggest that a corrective action is likely in store in the days or weeks ahead.


He also points out a recent study by BAML writing, “Then there is this tidbit:

We’re about to step into seasonality ditch: lowest 3-month returns Aug-Oct for S&P going back to 1928

Source: BoA ML pic.twitter.com/Q5S5JSQdvr

— Babak (@TN) July 29, 2016”


We found more statistics on the potentially soft market action in the coming weeks and months from The Fat Pitch. He writes, “An third reason to expect a reaction in August is that the month is seasonally weak and often volatile. Recall that July is typically the strongest month of the summer. In comparison, August is one of the weakest months, especially over the past 10 and 20 years (data from Ryan Detrick and Bloomberg).”





“But what sets August (and September) apart is not that the month ends badly but that the interim drawdown within the month can be severe. A 5% decline in August (or September) is nearly twice as likely as during any other month (data from Sam Stovall).”

Political Unrest

We are in the throes of election season and one can surely anticipate the mudslinging to kick into high gear. The race is tight as seen by the latest polling from Real Clear Politics.  Head-to-head nationally Clinton leads Trump by 1.1%, but adding in Johnson, Trump leads Clinton by a fraction. Add Stein to make it a four-way race and both are tied. A close race thus far so expect the rhetoric to really pick up from here.





According to Almanac Trader, “July’s big rally has pushed the DJIA well into incumbent winning territory. As you can see below this has not been typical July market action. The usual second half of July weakness never materialized. Once the market realized that Brexit was no imminent threat or a clear and present danger, stocks quickly erased the two-day post-Brexit selloff and rallied to new all-time highs on the DJIA and S&P 500 in relatively short order.

Since economic data has not impressed the Fed enough and continues to ebb and flow every month, it’s unlikely we’ll see another rate increase until after the election. Earning season went off without a hitch as companies overall did not disappoint Wall Street much, though we were not overly impressed.

Buoyed also by earnings numbers that mostly beat lowered forecasts and the promise of continued accommodative monetary policy for the foreseeable future, this rally has pushed the DJIA well above any of the rosiest scenarios for an election, which has historically, been a vote of confidence for the incumbent presidential party.”



The chart below shows that this market has been performing quite well when compared to other election years. The green line represents election years when there is no sitting President running and the red line represents the market performance this year thus far. What’s interesting on this chart is the orange line that shows how the stock market had traded in the years when the incumbent party won the election. If the market continues this pace it appears Clinton will hold the edge going into November.


As far as future market performance Jeff Hirsch writes, “If anything we should all find at least some solace in the continued civilized, yet enthusiastic and sometimes heated debates of the open political process that this great nation continues to be built on. However, as two of the most unfavorable candidates head into the home stretch of a virtual dead heat presidential election campaign, things are bound to get uglier and spook the market.”

This election year sell-off will most likely happen in August through September. According to Almanac Trader, since 1952 (when agriculture started to play less of a role in our economy) the third quarter of an election year is historically the weakest quarter on the year. The fourth quarter of an election year is the strongest. This holds with our notion that a pullback over the next weeks and months should be followed by an additional thrust upward.


David Kotok, the chief investment officer of Cumberland Advisors points out (via Business Insider), “After the Brexit vote took the wheel of the economy for a while, Japan's recent elections have also influenced global assets. On the horizon, the US presidential election should have a pretty firm grip on the market until voting finally happens in November.

"The race between Trump and Clinton is creating a whole lot of uncertainty," said Kotok. "People really aren't sure what to make of either candidate or the race, and it's going to make the market unstable until the election happens."

Add in Spanish and Italian elections in September and October, respectively, and there's almost no period for the rest of the year without some sort of political event.”


“Political events are harder to predict than some business events. Thus, markets are more likely to be caught flat-footed like they were after the Brexit vote, leading to wild swings in prices. Dealing with such swings is what will separate the good investors from the bad, according to Kotok.”

Long-Term Prospects Are Solid

The monthly chart of the S&P 500 shows a potential upward bias to the market longer-term. The market has recently broke out of its trading range and the monthly MACD has been improving and is on the verge of a long-term bullish cross. Both RSI (14) and stochastics have held up well during the recent sell-off and momentum seems to be improving. The same can be said for the Nasdaq on the monthly chart.



A recent post in See It Market states, “While some near-term trends have cooled, the longer-term industry group trends remain firm. Some 80% of the industry groups in the S&P 1500 are now in up-trends. The behavior of this indicator in 2016 is in sharp contrast to the deterioration that was seen over the course of not only 2015 but 2014 as well (when the pattern of lower highs and lower lows started to emerge). Without a significant change in character, this indicator suggests any pullbacks seen over the near term could limited in degree and duration.”


We recently commented about a potential “melt-up” in the market as earnings data improves and bullish sentiment takes hold. It has been stated by many that this coming melt-up will represent the fifth wave of the bull market according to Elliot Wave Theory. From The Fat Pitch, “Our best guess is that US equities are in the final "wave 5" of the 7 year bull market. In Elliot Wave terminology, bull markets advance in 5 waves: waves 1, 3 and 5 move higher while waves 2 and 4 are interim corrections. The basic structure is shown below.”



“One of the main defining characteristics of this pattern is that "wave 3" is normally the longest. In the current bull market, that would correspond to the long 2011-15 advance. "Wave 2" was the steep 20% correction in 2011 that some consider a bear market.  In comparison, "wave 4" is often a "flat" correction: this corresponds to the flat trading range that persisted through much of 2015 and the first half of 2016. The new highs for both SPX and NDX indicate that "wave 5" is now underway.”


“A literal interpretation of this pattern would imply that SPX is headed above 2500, about 20% higher. Instead of a price or calendar target, we think it makes much more sense to monitor the data. "Wave 5" will likely top when sentiment becomes excessively bullish. If waves 1 and 3 are characterized by "skepticism" and "acceptance", respectively, then the final push in a bull market is typically "euphoric". At the 2007 market top, fund managers' equity allocation was nearly 60% overweight and cash was under 3.5%. At the end of "wave 5", we will also start to see employment, housing and various measures of consumption start to flatten and weaken.”

The Return of Fundamentals

It’s no secret that corporate fundamentals have been weak. Earnings and revenue growth have been nonexistent through this latest rally. Some believe the latest rally stems more from a willingness from investors to move to risky assets as yields on fixed income plummeted. According to the folks at Deutsche Bank (via Business Insider), “According to Dominic Konstam and team, writing in a note Friday, the rally is about the declining equity risk premium, which is simply the excess return the stock market provides over a risk-free rate like bond returns.

The premium jumped after stocks plunged in the financial crisis, with investors demanding as much as 7% more from choosing stocks over bonds. It has now fallen closer to its historical norm of 2% as bond yields also fell, implying that the return investors require to be compensated for their risky investments in stocks has fallen.

The sovereign bond yields in many developed countries are at or near record lows. Yields on benchmark bonds in Germany and Japan plunged deeper into negative territory after the rush to government-debt markets sparked by the UK's decision to leave the European Union.

As nominal yields have fallen, investors have rotated into higher-yielding assets, Konstam said.

From the note:

"The current cycle stands out in that earnings have played almost no role in the SPX rally. In fact, earnings were a slight drag on equities and were only offset by an aggressive multiple expansion. More than 90 percent of the rally was attributed to a collapse in equity risk premium ... In sharp contrast, the equity gains in the 1980s and 2000s were all about earnings growth, and in 1990s earnings still accounted for more than half of the rally."”

Our view is that an improvement in the revenue and earnings outlook could be a net positive in a market that has already priced in a mild earnings recession. It still appears the US economy, albeit quite weak will avoid a recession and that may be enough to drive equities.

Indeed we seem to have gotten good news on the earnings front this week from FactSet. They write, “During the month of July, analysts lowered earnings estimates for companies in the S&P 500 for the quarter. The Q3 bottom-up EPS estimate (which is an aggregation of the EPS estimates for all the companies in the index) dropped by 0.7% (to $30.44 from $30.66) during this period…During the past year (4 quarters), the average decline in the bottom-up EPS estimate during the first month of a quarter has been 2.7%. During the past five years (20 quarters), the average decline in the bottom-up EPS estimate during the first month of a quarter has been 2.3%. During the past ten years, (40 quarters), the average decline in the bottom-up EPS estimate during the first month of a quarter has also been 2.3%. Thus, the decline in the bottom-up EPS estimate recorded during the first month of the third quarter was smaller than the 1-year, 5-year, and 10-year averages.”

It is understood that analysts will reduce their quarterly and annual estimates as the year progresses, but a significant decline in the rate of change in those downward revisions are a positive event. That appears to be what we are seeing.

They also note, “The blended (combines actual results for companies that have reported and estimated results for companies yet to report) revenue growth rate for the S&P 500 increased to 0.1% this past week, which is above the year-over-year decline of -0.3% at the end of last week and the year-over-year decline of -0.8% at the end of the second quarter (June 30). If the index reports growth in revenues for the quarter, it will mark the first time the index has seen year-over-year growth in sales Q4 2014 (2.0%).”

The revenue figures that have been reported thus far for 2Q16 have pushed the expected revenue growth figure into positive territory for 2Q16. Earnings growth expectations are still negative for 2Q16 but have also improved. Given the slowdown in the rate of deterioration of financial projections along with the magnitude of positive surprises (both revenue and earnings beats are above historical norms according to FactSet) means we could see corporate fundamentals improve beyond expectations. Should the global economic picture worsen then all bets are off. We need to keep a close watch on this.  

One professional that isn’t convinced of the rebound in corporate fundamentals is Byron Wien, vice chairman at Blackstone Group. In a recent article by Business Insider they go on to state, “The main problem is wage growth, according to Wien. Modest revenue growth, coupled with a lack of pricing power among companies, means that margins have to be squeezed as wages climb.

 "Profit margins are coming down and labor share of corporate GDP is going up," he said. "So my view is that there's a margins squeeze going on. You saw it in the first-quarter earnings, and I think you'll see it manifested throughout the year."

He also thinks that a correction is likely because of high stock market valuations and investor euphoria, although a bear market and recession are unlikely to happen.”

Indeed we have written in the past that margins have begun to deteriorate and significant margin contraction can lead to bad things in the US equity markets as seen in the chart below.


We could also make the argument that the market is 10% to 15% overvalued at current levels but the one bright spot is that the fundamental picture has started to improve. The chart below shows the trajectory of analysts twelve month forward bottom up EPS forecasts relative to the market. We can see that the downward trend in forward earnings forecasts have turned higher with the market. The chart below that confirms the trend showing an uptick in the slope of forecasted earnings. A pick-up in the rate of EPS acceleration would surely benefit stock prices.



Even the point of valuation is defended by some of the greatest minds on Wall Street. Richard Bernstein of Richard Bernstein Advisors in his latest commentary states, “Many income-centric investors believe that the equity market is significantly overvalued simply because the market PE seems high relative to history. However, PE ratios in isolation have not historically been good forecasters of future returns because PEs must be related to interest rates and inflation.

There is an old investment rule-of-thumb called the Rule of 20 that uses combinations of headline inflation and the S&P 500® PE to determine fair value. Our valuation models are, of course, more elaborate than the simple Rule of 20, but based on a more rigorous analysis of inflation and PE ratios, the current equity market appears, at worse, to be fairly valued. Investors forget that inflation was increasing leading up to the 2008 bear market. In fact, the CPI, which is a lagging indicator, peaked at 5.6% in July 2008. Today’s headline inflation is 1.0%.

The chart below shows combinations of inflation and valuations over the past 50 years or so. The current observation does not suggest investors need to be as defensive and income-centric as they are currently.”

Bottom Line: We have changed our thinking from the beginning of the year. We initially thought the market top was in but as the technical, behavioral and fundamental picture changed, so have our investment thesis.

We are preparing for a market melt-up as sentiment catches up with the easy monetary policy driven rally and improving corporate fundamentals. That said we believe the months of August and/or September will offer a pull-back in the market as an opportunity to increase long exposure.

We are nearly fully invested towards the long side currently but will start to raise cash (not go short) after one or two distribution days. Once the sell-off completes its course and as long as the new technical levels hold, we will use the opportunity of a pullback to rebalance our positions.

Joseph S. Kalinowski, CFA

Email: joe@squaredconcept.net

Twitter: @jskalinowski

Facebook: https://www.facebook.com/JoeKalinowskiCFA/

Blog: http://squaredconcept.blogspot.com/

Web Site: http://www.squaredconcept.net/



Additional Reading




No part of this report may be reproduced in any manner without the expressed written permission of Squared Concept Asset Management, LLC.  Any information presented in this report is for informational purposes only.  All opinions expressed in this report are subject to change without notice.  Squared Concept Asset Management, LLC is a Registered Investment Advisory and consulting company. These entities may have had in the past or may have in the present or future long or short positions, or own options on the companies discussed.  In some cases, these positions may have been established prior to the writing of the particular report. 

The above information should not be construed as a solicitation to buy or sell the securities discussed herein.  The publisher of this report cannot verify the accuracy of this information.  The owners of Squared Concept Asset Management, LLC and its affiliated companies may also be conducting trades based on the firm’s research ideas.  They also may hold positions contrary to the ideas presented in the research as market conditions may warrant.

This analysis should not be considered investment advice and may not be suitable for the readers’ portfolio. This analysis has been written without consideration to the readers’ risk and return profile nor has the readers’ liquidity needs, time horizon, tax circumstances or unique preferences been taken into account. Any purchase or sale activity in any securities or other instrument should be based upon the readers’ own analysis and conclusions. Past performance is not indicative of future results.
















Saturday, July 23, 2016

The Biotech Bottom


We’ve had a good bounce off the June 27 Brexit event. We had placed long positions as the S&P 500 bounced off the 2000 level. One of the sectors we moved into was large-cap biotechnology as represented by the iShares Nasdaq Biotechnology (IBB). The sector is up 17% from the lows vs. +9% for the S&P 500, so we are pleased with the relative performance. This sector has had a rough go of it this year and quite honestly could not seem to get out of its own way. It tried to bottom and rally a few times but eventually succumbed to the bears. We are watching very closely for weakness and we may start taking profits on our position if it appears the sector is breaking down once again. That said we understand there remains a good possibility that this sector will offer addition upside from here so we’re not ready to exit just yet.

Here are six items we are watching that we believe could propel this sector even higher from here.

1 – Valuation Trends

2 – Technicals

3 – Earnings Season and Short Interest

4 – Merger & Acquisition

5 – Pipeline & Catalysts

6 – Politics

Valuation Trends

We utilize the S&P 500 Biotechnology index to derive our fundamental data for the purposes of our screening. As seen in our dashboard reading below the sector trades 12.5x forward eps with expected forward earnings growth of 26%. This provides a PEG of 0.5 and offers one of the most favorable value profiles for this sector in almost a decade. We believe if the sector could continue to catch the bid there could be an additional 20% upside from here. We’d of course need to see several things happen over the next several weeks and months for this to happen and we’ll discuss each in a moment.


The chart below shows the earnings yield for the biotech sector is at 8%. This is a very attractive yield for the space showing significant undervaluation. The chart below that is the forward EPS value variance. This model shows how many standard deviations the sector is trading away from its fair value average near-term mean (two years). The sector is trading was trading two standard deviations below the mean. It has since recaptured the one standard deviation level but we find this momentum upward encouraging and increases the chances of higher prices in our view.






One needs to always be concerned about the “value trap”. Sure the sector is trading cheap for a reason. We understand the negative sentiment that has taken form around drug prices. At one point in time we had three presidential candidates (Trump, Clinton and Sanders) railing against the drug industry. Daily appearances by Martin Shkreli and alleged securities violations, Bill Ackman trying to keep Valeant Pharmaceuticals from going to zero and the pending outcome of the Medicare Independent Payment Advisory Board decision probably didn’t help.

One thing that we do not believe is that deteriorating fundamentals within the space was the cause of the declines. The sell-off was purely sentiment driven while the underlying fundamentals remained steadfast. The following charts show revenue and earnings expectations for the sector; profit margin for the sector; and the trend on earnings, book value and cash flows. With the exception of a slowing in the pace of growing book value (reddish/brown line in the third chart down) we don’t see a massive breakdown in fundamental trends. We take that as a good sign.






What’s also encouraging is the sectors cash-to-EV ratio. From Bloomberg research, “U.S. biotech companies' cash-to-EV ratios suggest that the sector is firmly in a bear market, but a silver lining is that it appears the sector is at its bottom. The ratio of U.S.-based companies in the Nasdaq Biotech Index with cash in excess of their EV is comparable with previous bottoms in 2009 and 2011, and it hasn't worsened beyond that. One could argue that the market continues to hold at this point.”





Technicals

Below is the weekly chart of IBB. I have enough scars on my hands from trying to catch falling knives in the past but there were a few items on the chart that enticed me to scale in from the Brexit lows. The sector had sold off in dramatic fashion from the middle of last year but stopped dead in its tracks at the 200 week moving average. It tested that level several times. It broke through to the downside briefly after Brexit but quickly retook the line and that was enough for me to get involved. We started to scale in at that point with an average price of low $250’s (green line) and set our two stops at key levels (two red lines) planning on selling half the position at our first stop and closing the position below the second stop. We never reached those levels. This isn’t an exercise in Monday morning quarterbacking, the point here is that the valuation and the support at these levels are encouraging and support higher prices ahead in our view. We think we have to make it through the resistance near the $290 level and then we could see a strong breakout. We also like the divergence between equity prices forming a base while MACD and RSI (14) have been trending higher. This further strengthens our view towards the sector.




We also like the weekly relative price performance chart of biotech vs. the S&P 500. There seems to be bullish divergences in place and leads us to the conclusion that biotech will outperform the general market in a big way just as we have seen off the June lows.




On the IBB daily chart we had a bullish MACD cross and RSI (14) has risen above 50. These are both good things to see when long the sector but one needs to be weary of the overhead resistance that is now approaching. A break above the April and June peaks and a retaking of the 200 day moving average would be an exceptionally bullish sign and we would in all likelihood take an even stronger position.




Short Interest

We came across this article in Seeking Alpha (Via Yahoo Finance). The author went on to write, “According to the NASDAQ, on the settlement of September 30, 2015, IBB short interest surged 23.82% to 11.54 million shares, since Hillary Clinton sent out a tweet on September 21, 2015 saying, “Price gouging like this in the specialty drug market is outrageous. Tomorrow I’ll lay out a plan to take it on. -H “.

The tweet was in response to then CEO of Turing Pharmaceuticals Martin Shkreli, after Turing raised the cost of an older antibiotic drug, Daraprim, by more than 50-fold and said the drug was still a bargain at $750. Since then, IBB’s short interest has dropped to 5.7 million shares, as of settlement on June 15,

2016, or about 22.89% of shares outstanding,” according to a Seeking Alpha analysis of biotech short interest.”

““From a technical viewpoint, IBB bounced off the $240 support level, or the February low, and broke back into the symmetrical triangle chart pattern. There are three major resistances at $280, $285 and $290, respectively, as the IBB continues to move higher. Closing and staying above the 200-day moving average will trigger a short squeeze,” adds Seeking Alpha.”

I checked the latest numbers from Bloomberg and as of 6/30/16 there were $5.7mm shares outstanding which represents 2.4x average trading volume. These figures are slightly elevated but for the most part not at extremes. This is something we will continue watching.

Should there be a short squeeze coming, surely the earnings report by Biogen rattled a few cages. There are many biotech stocks that have retaken their 200 DMA and are breaking out. Amgen, Inc. (AMGN), Celgene Corporation (CELG) and Biogen (BIIB) are all large weightings in the S&P 500 biotech sector and large holdings in IBB. It looks like we broke the neckline of a reverse head-and-shoulders formation on CELG.







M&A Activity

We’ve already had several high profile Merger & Acquisition activity this year and given prolonged accommodative monetary policy and cheap access to cash along with the low valuation within the sector we could see that pace of M&A activity continue through the remainder of the year and into next year. This would be a net bullish event for the entire sector in our view.

Recent headlines from Bloomberg Research:

“M&A in the biotech sector may be poised for a comeback after a relatively lackluster start to the year. A sustained period of active M&A came to a halt in 1Q, as valuations crashed and dealmakers avoided the volatility. Still, the need exists, especially for companies such as Gilead, Biogen and some large pharmas, where the right deal could ease concern that key assets have reached their growth ceilings. The pronounced change of tone suggests M&A discussions may be back on the radar.”

“Smaller biotech companies may be forced to the deal table, given the slowdown in secondary financing. Market volatility in the last 12 months will have probably made further public offerings unattractive, corroborated by the slowdown in IPOs. Smaller biotechs typically don't finance via debt, so if the markets aren't ripe for further equity offerings, these companies --particularly those with less than two years of cash in the bank -- may have issues funding R&D and day-to-day operations.”

“Recent commentary from biotech buyers suggest broadly increasing comfort with the valuations of potential targets. While some comments were also made that there could be room for a bit more of a price correction, this may be posturing, and overall sentiment appears to be in stark contrast to that at the beginning of the year. Biotech is typically purchased by large pharma and big biotech companies seeking new potential growth engines, technology, or pipeline fillers.”

“Among big biotech companies, Gilead, Biogen and Amgen are more likely to be seriously evaluating M&A options to bolster their pipelines in 2016. Gilead and Biogen have openly hinted at this on earnings calls, and the Financial Times reported Amgen is hunting for a potential deal of up to $10 billion. Celgene is by nature deal-centric, though typically resorts to licensing. Gilead has commented that a large merger is possible, which may help challenge consensus expectations of slowing revenue.”

“Pharma industry access to cheap cash amid loose monetary policy may be prolonged with the U.K.'s Brexit vote. U.S. and European large pharma companies have more than $170 billion in debt capacity to deploy for M&A, assuming leverage of 2.5x.”




Pipeline & Catalysts

According to recent statistics derived from Bloomberg research, it would appear that the pipeline for clinical and regulatory catalysts is the most robust it has been in the past five years. Much of these anticipated announcements are expected towards the latter part of this year and that could be an added bullish factor to send stock prices higher (assuming a majority of the news-flow is positive). With the bulk of catalysts happening in 4Q16, this could continue to shift positive sentiment within the sector.



Politics

We’ve managed to get through the RNC without direct mention of drug pricing controls. We’ll see this week if the drug industry is demonized at the DNC. Given the choice of the two V.P. picks by each of the candidates, it appears there will now be a shift towards the center to try to appeal to the independent and swing voters. Recent polling shows that economic concerns and the fight against terrorism is still the predominate concerns of the country. Given the recent wave of global violence, Trumps “law and Order” candidacy and the aggressive tactics of the Republican base against Secretary Clinton, we would guess that she has enough to address and drug pricing will take a much more subdued role in her massage than when she was battling Bernie Sanders in the primaries. The chart below is the World Conflict Index from BBVA Research. As can be seen, it has been edging higher recently and will be a focal point of the coming election season in our view.




We believe this could be a positive for the sector that has been at the forefront of controversial political concerns. The decision to stall and delay the Medicare Independent Payment Advisory Board should also be seen as a net benefit for biotech sentiment. Based on political articles that we read, it also appears more likely the House and more importantly the Senate should remain in Republican control. We also believe this to be a net benefit for the sector.  

Bottom Line: We are long the biotech sector through the purchase of IBB. The sector has been basing for a while and we believe it could be on the verge of a breakout for the reasons cited above. If we do breakout above the 200 week moving average to the upside and retest to hold that level, we will be increasing our exposure to the sector as we believe there is much upside to be garnered. If the sector breaks down, we will lessen our long exposure with a willingness to re-enter should the support of the past continue to hold.

Be wary of potential market weakness coming in August through October. We’ll be tightening our stops up here.


Joseph S. Kalinowski, CFA


Email: joe@squaredconcept.net

Twitter: @jskalinowski

Facebook: https://www.facebook.com/JoeKalinowskiCFA/

Blog: http://squaredconcept.blogspot.com/

Web Site: http://www.squaredconcept.net/


No part of this report may be reproduced in any manner without the expressed written permission of Squared Concept Asset Management, LLC.  Any information presented in this report is for informational purposes only.  All opinions expressed in this report are subject to change without notice.  Squared Concept Asset Management, LLC is a Registered Investment Advisory and consulting company. These entities may have had in the past or may have in the present or future long or short positions, or own options on the companies discussed.  In some cases, these positions may have been established prior to the writing of the particular report. 


The above information should not be construed as a solicitation to buy or sell the securities discussed herein.  The publisher of this report cannot verify the accuracy of this information.  The owners of Squared Concept Asset Management, LLC and its affiliated companies may also be conducting trades based on the firm’s research ideas.  They also may hold positions contrary to the ideas presented in the research as market conditions may warrant.


This analysis should not be considered investment advice and may not be suitable for the readers’ portfolio. This analysis has been written without consideration to the readers’ risk and return profile nor has the readers’ liquidity needs, time horizon, tax circumstances or unique preferences been taken into account. Any purchase or sale activity in any securities or other instrument should be based upon the readers’ own analysis and conclusions.
Past performance is not indicative of future results.


Sunday, July 10, 2016

Preparing for the Irrational Melt-Up


If I were to shut the television off and completely stop watching stock market levels, only focusing on market sentiment and safe haven assets, one would believe US equities are in the throes of a market sell-off that is nearing its completion and possibly forming a bottom. Yet here we are making new 52 week highs and quickly approaching all-time highs, at least for large cap stocks. Negative sovereign debt yields and a risk-on and off US market is a unique education so we are taking notes.

Last week we wrote about the prospect of US equities breaking to new highs. We also commented on subdued market sentiment and fund flows as the fuel that could drive the market much higher. We have found additional evidence of that theory in our reading this week.   

In Yahoo Finance this past week, “When volatility spikes in the financial markets, so does fear of an impending market crash. This fear went parabolic last month as the UK unexpectedly voted to leave the European Union. In the days that followed, markets around the world sold off sharply.

"Feelings of 'This is it!' rise again," Oppenheimer's Ari Wald said.

Ironically, history shows that fear of a crash has a poor track record of predicting crashes. Conversely, some of history's worst crashes came when no was expecting one.

"We continue to note that the sentiment backdrop is far from extreme optimism and instead quickly shifts to gloom and doom during market downturns," Wald wrote in a note to clients. "We saw this again last week as shown by a spike in the number of news stories referencing the words 'Stock Market Crash' to its highest level in years. For comparison purposes, there were significantly fewer occurrences of this through the topping process in 2007."

In other words, very few people were looking into stock market crashes before the last big crash actually happened.”



“"Our view is that with many investors seemingly eager to call the next market crash, the risk of one is likely not yet significant," Wald said.

Yale School of Management tracks this fear through surveys, which feed into the school's proprietary Crash Confidence Index. The index represents the percentage of respondents who think there's a less than 10% probability the market crashes in the next six months.

Similar to Wald's observation, Yale's Crash Confidence Index showed that many folks didn't fear a crash as the stock market peaked and tumbled from 2007 through 2008.”


“"Crash confidence reached its all-time low, both for individual and institutional investors, in early 2009, just months after the Lehman crisis, reflecting the turmoil in the credit markets and the strong depression fears generated by that event, and is plausibly related to the very low stock market valuations then," Yale analysts observed. "The recovery of crash confidence starting in 2009 mirrors the strong recovery in the stock market."

In other words, the bottom in the stock market coincided with peak fears of an impending market crash.

Some of Wald's peers on Wall Street are coming to similar conclusions that the fear these days may be overblown.

“In June, the Sell Side Indicator — our measure of Wall Street’s bullishness on stocks — fell for the third month in a row to 50.7 (from 51.6), its lowest level in three years,” Bank of America Merrill Lynch’s Savita Subramanian said on Friday. "The indicator is now firmly in 'Buy' territory … While sentiment has improved significantly off of the 2012 bottom — when this indicator reached an all-time low of 43.9 — today’s sentiment levels are still well-below where they were at the market lows of March 2009.””


“Subramanian says this indicator, which is based on recommended equity allocations among Wall Street strategists, is predicting a 12-month total return of over 21% for the S&P 500 (^GSPC).

Over at Citi, strategist Tobias Levkovich sees a similar signal coming from his firm's proprietary Panic/Euphoria model, which is based on various market measures of sentiment.

“[S]entiment remains quite poor, similar to the lows in 2011-12 when investors should have been buying stocks,” Levkovich said following the Brexit vote.”


As mentioned last week, it seems the next market correction/bear market is so anticipated that it just may not happen yet.

Short-term technical

Just a few interesting market observations last week. On CNBC Canaccord Genuity chief investment strategist Tony Dwyer said “the combination of historical precedent and fundamental backdrop suggests a 15 to 20 percent upside over the next 6-12 months.”

“Here's what happened: On June 28 and June 29, 90 percent of the New York Stock Exchange (NYSE) volume was positive. "If you go back to look at 1950 on just occurrences, when you had two upside 90 percent days you have never been negative three, six and twelve months later. As a matter of fact, your median gains are 12 percent, 18 and a half percent, and 29.2 percent," Dwyer recently told CNBC's "Futures Now."”

“"The data is very clear. The market is up every time after you get this kind of buying thrust that we've had" over last week, he said. "And, the last time that you had a similar environment of low interest rates, flat yield curve, European crisis.... that was the time to buy the banks," said Dwyer.”

Indeed we found something similar on Dana Lyon’s Tumblr, “While the S&P 500 missed out on an all-time high today by 92 cents, it did receive consolation in the fact that it was a 52-week high. It was also the first such high in more than a year. Since 1950, this was the 13th time the index has had to wait more than a year to hit a new 52-week high.”

“How did the index respond following the previous 12 long waits? Quite well, thank you very much. As the table shows, the median return was positive across every time frame, from 1 week to 2 years. Not only that, but gains were unanimous 1 and 2 years later.”



John Murphy from Stockcharts.com also made the case for higher equities from here. He goes on to write, “My May 25 message referred to the flat line drawn over the highs of the fourth quarter and this spring as a "neckline" which is normally part of bullish "head and shoulders" bottoming formation (see Chart 1). To complete that bottom, however, prices have to close decisively above the neckline. That hasn't happened yet. Technical indicators, however, suggest that an eventual upside breakout is likely. First of all, the 14 week RSI line (top of chart) remains above its 50 line which reflects positive momentum. More importantly, weekly MACD lines (below chart) have risen above a falling trendline extending back to the middle of 2014. Both MACD lines are also above their zero lines. It was the bearish divergence in those two lines in mid-2015 that signaled problems ahead (red arrow). At the moment, the two weekly MACD lines are sending a more bullish message. So is the fact that the blue 10-week average is well above the red 40-week line. All of those indicators (combined with a bullish chart pattern) portray a positive image.”


“One of the hallmarks of a potential "head and shoulders" bottom is the volume pattern. In other words, volume should form a bottoming pattern of its own. And it appears to be doing that. The green line above Chart 2 is an On Balance Volume (OBV) line of the NYSE Index. The OBV line is a cumulative total of upside and downside volume. Volume is added on up days and substracted on down days. As a result, the trend of the OBV line tells whether there's more buying or selling. More importantly, it should trend in the same direction of the price action. In many cases, the OBV leads the price action higher. The green line in Chart 2 shows the OBV line forming a potential "head and shoulders" pattern of its own. More importantly, the OBV line has already risen above its "neckline" and is close to exceeding its October high. It looks to me like the OBV line has already bottomed. That increases the odds that prices will eventually trend in the same direction. I'll leave it up to you to decide that for yourself.”


He goes on to point out that the NYSE AD line and the common stock only NYSE AD line are hitting new highs ahead of the market. That is also taken as a bullish signal.




Sovereign Debt

What is the story with global bond yields? Our 10-year yield hit lows of 1.37% while our 30-year fell to 2.11%. Imagine that, 2.11% for 30 years. And to think these yields are high relative to other nations. From Wolf Street, “The German government, paragon of fiscal rectitude at the moment, one of the few AAA-rated governments left on earth, is able to charge investors for lending it money: the 10-year yield ended the week at a negative -0.187%; the 30-year yield is still positive at 0.35%, but creeping closer to zero.

In Japan, it’s even worse. Fiscally, Japan is the opposite of Germany. It has a lowly A+ credit rating, a gross national debt that has ballooned to 250% of GDP, by far the worst in the developed world, and mega-deficits year after year. Yet its lost-cause debt sports a 10-year yield of negative -0.288%. Even the 30-year bond is dabbling with zero.

Swiss government bonds are the negative-yield-absurdity trailblazers: the 10-year yield, at -0.60%, is the most negative 10-year yield in the world. Even the 30-year yield is negative.”

“At the end of May, the total amount of government debt with negative yields had reached $10.4 trillion. By June 27, it had jumped to $11.7 trillion, according to Fitch Ratings. Since then, even more debt has skidded into negative-yield absurdity, now exceeding $12 trillion, and moving inexorably higher.

“Merrill Lynch now says 29% of the global fixed income market is sporting negative rates, up from 24% pre-Brexit,” explained Christine Hughes, Chief Investment Strategist at OtterWood Capital, in her newsletter. It’s “a continued march south in global yields courtesy of the relentless demand for bonds””

The chart below from Pension Partners highlights the current sovereign debt market.


So there is a war being waged. Bonds vs. stocks. Simultaneous risk-on and off. If the bond market proves to be right and win the battle, then we are looking at global deflation and most likely a very bad period of global economic growth and equity returns. If stocks win the day, then we should expect the bull to resume and global yields rise. This will hurt bond holders and could be the blow-off top to the bond bubble that has been in place for some time.

The folks at Pension Partners write, “The behavior of bonds is wildly disturbing globally, and the US is not immune.  If bonds are right, then a deflation tsunami is coming.  And that means stocks likely have a lot of downside and volatility to come in the years ahead. If bonds are right, we are at the end of the bull markets and period of low volatility for stocks…If indeed stocks are right about the future, then it is the end of the bond rally, and rising rates finally will come.  We should all be cheering for that to be the case.  Either way though, I believe we are nearing the end of one of the most historic disconnects of all time.  When we find out the answer of who is right is unclear.  Every day that goes by though, we are closer to one class of investors being dangerously wrong.”

Based on our reading it appears many strategists believe the bond rally will soon end. Unfortunately, many of these same strategists have being calling for the end of the bond boom for years now and have completely missed the mark. From Bloomberg, “And yet here comes Goldman Sachs, sounding an alarm yet again about how U.S. yields are poised to increase and that investors are overreacting to Britain's vote to leave the European Union.

"The U.K. is not a global economic bellwether, and hence any economic activity slowdown should have a limited impact," Rohan Khanna, a London-based interest rates strategist at Goldman, wrote in a note cited by Bloomberg News reporter Kevin Buckland on Tuesday.

Goldman is not a complete outlier when it comes to believing Treasury yields will rise soon. Bank analysts surveyed by Bloomberg still predict that U.S. benchmark borrowing costs will generally increase this year.”


The article goes on to give several reasons why a rise in rates in the near-term are unlikely citing (correctly so in our opinion); (1) cross-country yield correlations; (2) The remaining hangover effects of Brexit (whatever they may be) and (3) lack of inflation.

In Bill Gross’s June newsletter, he summed up the dilemma facing fixed income investors. He writes, “Since the inception of the Barclays Capital U.S. Aggregate or Lehman Bond index in 1976, investment grade bond markets have provided conservative investors with a 7.47% compound return with remarkably little volatility…GMO’s Ben Inker in his first quarter 2016 client letter makes the point that while it is obvious that a 10-year Treasury at 1.85% held for 10 years will return pretty close to 1.85%, it is not widely observed that the rate of return of a dynamic “constant maturity strategy” maintaining a fixed duration on a Barclays Capital U.S. Aggregate portfolio now yielding 2.17%, will almost assuredly return between 1.5% and 2.9% over the next 10 years, even if yields double or drop to 0% at period’s end. The bond market’s 7.5% 40-year historical return is just that – history. In order to duplicate that number, yields would have to drop to -17%! Tickets to Mars, anyone?” {Emphasis Added}

Risk-off prevails despite the recent run in equities. In the chart below we are looking at the relative performance between long yields (TLT) and the S&P 500 (SPY). The channel is trending lower with RSI (14) below 50 and a negative MACD cross. The same can be said when comparing US equities to investment grade bonds (AGG). This doesn’t necessarily mean stocks will head lower; it points out that treasuries are outperforming stocks to this point. This is not a ringing endorsement for strong economic growth or a positive equity investment environment.

That said, we will be watching closely as (if) the stock market starts breaking new all-time highs. If we see an improvement in contrarian market sentiment and fund flows improve then that will be the fuel higher. The money flowing back into equities could very well come from the risk-off sectors that remain elevated.



In fact, across many risk-off safe haven assets, the US stock market, while rallying is underperforming. Gold, silver and the Japanese Yen are all considered safe haven assets and they continue to do quite well against US equities.




Bottom Line: So here’s what needs to happen. I am already long into this potential rally. If we break new highs in the US equity markets and safe-haven assets start to weaken relative to US equities and we get renewed leadership within the market (i.e. once utilities and consumer staples stop being the best performing sectors) then we will be much more aggressive in our long positions. Forgetting market fundamentals, global economic growth and corporate earnings for a second, the market is on the cusp of an irrational blow-off top driven by sentiment and fund flows stemming from sector rotation. This could be the opportunity to get some decent returns out of what has been a dismal year for many asset managers.

If we start to breakdown, then we will wait for a retest and breach of the February lows and position our portfolio accordingly, focusing on safe-haven and flight to quality issues. The market will breakout or breakdown. We don’t have the direction with certainty but we do have our strategy prepared for either event.



Joseph S. Kalinowski, CFA





Email: joe@squaredconcept.net

Twitter: @jskalinowski

Facebook: https://www.facebook.com/JoeKalinowskiCFA/

Blog: http://squaredconcept.blogspot.com/

Web Site: http://www.squaredconcept.net/







Additional Reading

On the stock market







On bond yields

Bond Yields: The Anti-Risk Bubble? – A Wealth of Common Sense



On Gold Prices




No part of this report may be reproduced in any manner without the expressed written permission of Squared Concept Asset Management, LLC.  Any information presented in this report is for informational purposes only.  All opinions expressed in this report are subject to change without notice.  Squared Concept Asset Management, LLC is a Registered Investment Advisory and consulting company. These entities may have had in the past or may have in the present or future long or short positions, or own options on the companies discussed.  In some cases, these positions may have been established prior to the writing of the particular report. 

The above information should not be construed as a solicitation to buy or sell the securities discussed herein.  The publisher of this report cannot verify the accuracy of this information.  The owners of Squared Concept Asset Management, LLC and its affiliated companies may also be conducting trades based on the firm’s research ideas.  They also may hold positions contrary to the ideas presented in the research as market conditions may warrant.

This analysis should not be considered investment advice and may not be suitable for the readers’ portfolio. This analysis has been written without consideration to the readers’ risk and return profile nor has the readers’ liquidity needs, time horizon, tax circumstances or unique preferences been taken into account. Any purchase or sale activity in any securities or other instrument should be based upon the readers’ own analysis and conclusions. Past performance is not indicative of future results.